# LEfSe vs. ANCOM: Choosing the Right Tool for Biomarker Discovery in Metagenomic Studies ## Key Takeaways - LEfSe employs a Kruskal-Wallis test followed by Linear Discriminant Analysis (LDA), offering high sensitivity for exploratory biomarker discovery but demonstrating poor control of the False Discovery Rate (FDR), potentially leading to inflated false positives. - ANCOM and its variant ANCOM-BC address the compositional nature of microbiome data through log-ratio transformations and pairwise testing, providing robust FDR control suitable for confirmatory analyses and validation studies. - The choice between LEfSe and ANCOM significantly impacts identified biomarkers, with LEfSe being more liberal and ANCOM more conservative, necessitating a complementary workflow where LEfSe generates candidates and ANCOM validates them. - Compositionality is a critical challenge in microbiome data; ignoring it, as LEfSe does not explicitly address, can result in spurious differences, whereas ANCOM's log-ratio approach is designed to mitigate these artifacts. - ANCOM-BC offers bias correction to estimate absolute abundances and provides effect size estimates with confidence intervals, enhancing its utility for meta-analysis and direct comparison of findings, unlike the original ANCOM which only provides binary significance. - For reproducible research, meticulous documentation of tool versions, parameters, normalization strategies, and zero-handling methods is paramount, especially when integrating multiple differential abundance tools. --- Researchers investigating microbial communities face a persistent problem: identifying which taxa truly differ between experimental groups. The two most frequently discussed tools for this task are linear discriminant analysis effect size (LEfSe) and analysis of composition of microbiomes (ANCOM). Both aim to detect differentially abundant microbes, but they rest on different statistical foundations, handle compositional data differently, and produce results that can diverge substantially on the same dataset. This article provides a head-to-head comparison of LEfSe and ANCOM, highlighting their statistical foundations, sensitivity to compositional effects, and appropriate use cases, so that researchers can make an informed choice before committing to an analysis pipeline. The choice between LEfSe and ANCOM affects which taxa you report as biomarkers, how confident you can be in those findings, and whether your results will replicate in independent datasets. Studies that apply multiple differential abundance methods to the same microbiome data consistently show limited overlap in detected taxa across tools, even when the underlying biological signal is identical. Understanding the strengths and limitations of each approach is therefore essential for any researcher working with 16S rRNA amplicon sequencing or shotgun metagenomic data. ## The Core Problem: Compositionality in Microbiome Data Microbiome sequencing data are compositional by nature. A sequencing run produces read counts that reflect the relative abundance of each taxon within a sample, not the absolute number of organisms. If one taxon increases in abundance, the relative proportions of all other taxa must decrease, even if their absolute numbers remain unchanged. This constraint creates spurious negative correlations between taxa and complicates any statistical comparison that assumes counts are independent. The compositional problem is the central challenge that differentiates microbiome differential abundance analysis from standard genomic or transcriptomic comparisons. Tools that ignore compositionality can produce false positives, identifying taxa as differentially abundant when the observed difference is merely an artifact of changes in other taxa. The choice of normalization and transformation method is therefore a critical decision that precedes any statistical testing. LEfSe and ANCOM take fundamentally different approaches to this problem. LEfSe applies a normalization step followed by nonparametric testing and linear discriminant analysis to estimate effect size. ANCOM explicitly models the compositional structure of the data using log-ratio transformations, which are mathematically designed to handle compositional constraints. A newer variant, ANCOM-BC, extends this framework with bias correction to estimate absolute abundances from relative data. The practical consequence of these differences is that LEfSe and ANCOM often disagree on which taxa are significant. A benchmark study comparing eight differential abundance tools found that LEfSe achieved high sensitivity but failed to adequately control the false discovery rate, while ANCOM and ANCOM-BC successfully controlled FDR with acceptable sensitivity [1]. This trade-off between sensitivity and specificity is the central consideration when choosing between these tools. ## Statistical Foundations of LEfSe LEfSe was developed to identify biomarkers that explain differences between two or more biological conditions. The method operates in three stages. First, it performs a nonparametric factorial Kruskal-Wallis sum-rank test to detect features with significant differential abundance between classes. Second, it uses a Wilcoxon rank-sum test to check biological consistency among subclasses. Third, it applies linear discriminant analysis to estimate the effect size of each differentially abundant feature. The linear discriminant analysis step is what distinguishes LEfSe from simpler differential abundance tests. LDA projects the data onto a lower-dimensional space that maximizes separation between groups, then ranks features by their contribution to that separation. The output includes an LDA score for each significant feature, which researchers commonly use to filter results and visualize biomarkers in bar plots or cladograms. LEfSe is designed for exploratory analysis and hypothesis generation. It is computationally efficient, easy to run, and produces visually appealing results that are widely used in microbiome publications. The tool accepts a feature table with taxonomic counts and a mapping file with sample metadata, making it accessible to researchers with limited bioinformatics experience. However, the statistical foundations of LEfSe have been criticized. The Kruskal-Wallis test and Wilcoxon rank-sum test are nonparametric and do not assume normality, but they do assume independence of observations. The LDA step assumes that features are normally distributed within groups and that covariance matrices are equal across groups, assumptions that rarely hold for microbiome count data. More importantly, LEfSe does not explicitly account for the compositional structure of microbiome data, which can lead to inflated false positive rates. A benchmark study comparing LEfSe against seven other tools found that it achieved high sensitivity but poor FDR control [1]. This means LEfSe tends to identify many taxa as differentially abundant, but a substantial proportion of those identifications may be false positives. For exploratory analysis where the goal is to generate candidate biomarkers for later validation, this liberal behavior may be acceptable. For confirmatory studies where false positives are costly, it is a serious limitation. ## Statistical Foundations of ANCOM ANCOM was developed specifically to address the compositional nature of microbiome data. The method is built on the principle that absolute abundances cannot be estimated from relative data without external information, but ratios of abundances can be compared across samples. ANCOM therefore transforms the data into log-ratios and tests whether the ratio of each taxon to all other taxa differs between groups. The ANCOM algorithm works by testing each taxon against every other taxon in the dataset. For a dataset with m taxa, this produces m-1 pairwise comparisons per taxon. A taxon is declared differentially abundant if a significant proportion of its pairwise comparisons reject the null hypothesis. This approach avoids the need to choose a reference taxon, which is a common source of bias in ratio-based methods. ANCOM-BC, the bias-corrected extension, adds an offset term to account for the sampling fraction of each sample. This correction allows ANCOM-BC to estimate absolute abundances from relative data, at least approximately, and provides confidence intervals for effect sizes. The bias correction is a significant improvement over the original ANCOM, which only provided a binary significance call without effect size estimates. The compositional approach of ANCOM has a strong theoretical foundation. Log-ratio transformations are the standard mathematical framework for analyzing compositional data, and they eliminate the spurious correlations that arise from the closure constraint. ANCOM and ANCOM-BC have been shown to control the false discovery rate in benchmark studies, making them more reliable than LEfSe for confirmatory analyses [1]. The cost of this rigor is computational complexity and reduced sensitivity. ANCOM performs a large number of pairwise tests, which can be computationally intensive for datasets with thousands of taxa. The multiple testing burden also reduces statistical power, meaning ANCOM may miss true differences that LEfSe would detect. ANCOM-BC mitigates some of these issues but still tends to be more conservative than LEfSe. ## At a Glance: LEfSe vs. ANCOM Comparison | Feature | LEfSe | ANCOM / ANCOM-BC | |---------|-------|------------------| | Statistical approach | Kruskal-Wallis test followed by linear discriminant analysis | Log-ratio transformation with pairwise testing across taxa | | Compositional handling | None explicitly, uses relative abundance normalization | Explicitly models compositionality through log-ratios | | False discovery rate control | Poor, high sensitivity but inflated FDR | Good, controls FDR in benchmark studies | | Effect size output | LDA score for each significant feature | ANCOM-BC provides effect size estimates with confidence intervals | | Computational cost | Low, fast on typical datasets | Higher, many pairwise comparisons required | | Best use case | Exploratory analysis, hypothesis generation, visualization | Confirmatory analysis, validation, studies requiring FDR control | | Typical workflow position | Initial screening before validation | Validation of candidate biomarkers from exploratory tools | ## Practical Workflow: Integrating LEfSe and ANCOM in Metagenomic Studies A robust biomarker discovery workflow does not rely on a single tool. The limitations of each method suggest a complementary approach: use LEfSe for exploratory screening to generate candidate taxa, then validate those candidates with ANCOM or ANCOM-BC to confirm that they survive compositional correction and FDR control. This two-stage strategy leverages the sensitivity of LEfSe and the specificity of ANCOM. The workflow begins with quality control of raw sequencing data. For 16S rRNA amplicon data, this involves removing low-quality reads, trimming primers, and clustering or denoising into amplicon sequence variants. For shotgun metagenomic data, quality control includes adapter trimming, host read removal, and taxonomic classification or metagenome assembly. The [Galaxy Training Network](https://training.galaxyproject.org/) provides accessible tutorials for these preprocessing steps, and the [nf-core documentation](https://nf-co.re/docs) describes community-standard pipelines for reproducible analysis. After preprocessing, the feature table is normalized. LEfSe typically uses relative abundance normalization, where each sample's counts are divided by the total count and multiplied by a scaling factor. ANCOM and ANCOM-BC use different normalization strategies. ANCOM-BC estimates sampling fractions directly from the data, while other ANCOM implementations may use centered log-ratio transformation or trimmed mean of M-values normalization. The choice of normalization affects downstream results. A study introducing the metaGEENOME framework found that integrating counts adjusted with trimmed mean of M-values normalization and centered log-ratio transformation with generalized estimating equation models improved FDR control compared to several existing tools [1]. This finding underscores that normalization is an active component of the statistical model, not a neutral preprocessing step. Once normalized, the data are ready for differential abundance testing. LEfSe can be run through its original command-line interface or through web-based implementations. ANCOM and ANCOM-BC are available as R packages through [Bioconductor](https://bioconductor.org/), which provides official package documentation and installation instructions. Researchers should document the exact version of each tool and the parameters used, as these details affect reproducibility. The results from LEfSe and ANCOM should be compared systematically. Taxa that are significant in both analyses are strong biomarker candidates. Taxa that are significant only in LEfSe may be false positives driven by compositional artifacts. Taxa that are significant only in ANCOM may be true differences that LEfSe missed due to its normalization approach. The overlap between methods provides a measure of confidence in the findings. A study of gut microbiota in temporal lobe epilepsy illustrates this workflow. The researchers used LEfSe with Benjamini-Hochberg false-discovery-rate correction for initial differential abundance assessment, then independently validated the findings using ANCOM-BC to account for the compositional nature of microbiome data [2]. This dual approach allowed them to identify species-level signatures in drug-resistant epilepsy while acknowledging the exploratory nature of their findings given the modest sample size. ## Data Inputs and Quality Checks The quality of differential abundance results depends entirely on the quality of the input data. Both LEfSe and ANCOM require a feature table where rows represent taxa and columns represent samples, with counts or relative abundances in each cell. A mapping file linking sample IDs to experimental groups is also required. The feature table should be generated from a well-validated taxonomic classification pipeline, and the mapping file should be checked for consistency with the feature table. Several quality checks should be performed before running differential abundance analysis. First, verify that the sequencing depth is adequate for the expected diversity of the community. Samples with very low read counts may not capture rare taxa, leading to spurious zeros in the feature table. Second, check for batch effects or technical variation that could confound the biological signal. Third, examine the distribution of counts across samples to identify outliers that may need to be removed or downweighted. The [NCBI Data Resources](https://www.ncbi.nlm.nih.gov/) provide access to reference databases and sequence archives that can be used to validate taxonomic assignments. The [EMBL-EBI Training](https://www.ebi.ac.uk/training) portal offers learning pathways for bioinformatics data analysis, including modules on sequence quality control and taxonomic profiling. These resources can help researchers establish robust preprocessing workflows before attempting differential abundance analysis. Sparsity is a particular challenge for microbiome data. Many taxa are present in only a subset of samples, creating a large number of zeros in the feature table. LEfSe handles zeros by treating them as absent, which can bias results if zeros are not randomly distributed across groups. ANCOM's log-ratio transformation cannot handle zeros directly, so researchers must apply a pseudocount or use a zero-replacement strategy before analysis. The choice of zero-handling method can affect results, and this decision should be documented in the methods section. ## Options and Tradeoffs: When to Use Each Tool The choice between LEfSe and ANCOM depends on the research question, the study design, and the consequences of false positives versus false negatives. There is no universally superior tool, and the best choice varies by context. LEfSe is appropriate when the goal is exploratory hypothesis generation. Its high sensitivity ensures that potential biomarkers are not missed, and its visualization tools make it easy to communicate results to a broad audience. LEfSe is also computationally efficient, making it suitable for large datasets or for initial screening before more rigorous analysis. The trade-off is a higher false positive rate, which means that LEfSe results should be interpreted as candidates for validation instead of confirmed biomarkers. ANCOM and ANCOM-BC are appropriate when the goal is confirmatory analysis or when false positives are costly. The compositional correction and FDR control make these tools more reliable for studies that will inform clinical decisions or guide further experiments. The trade-off is reduced sensitivity, which means that some true differences may be missed. ANCOM-BC provides effect size estimates that are useful for meta-analysis or for comparing results across studies. A study of chemotherapy toxicity in colorectal cancer patients illustrates the practical consequences of tool choice. The researchers evaluated six differential abundance methods, including LEfSe and ANCOM-BC, and found substantial variability across methods with limited overlap in detected taxa [3]. ANCOM-BC showed the most consistent overall performance across analytical scenarios, but trade-offs remained between taxa detection, ranking, and direction of association. This finding suggests that no single tool is sufficient and that method choice should be guided by the specific research context. For studies with small sample sizes, the choice of tool becomes even more critical. A study of gut microbiota in temporal lobe epilepsy with 30 patients and 30 controls found that ANCOM-BC identified species-level signatures that were not apparent from diversity indices alone [2]. The researchers emphasized that their findings were exploratory and hypothesis-generating given the modest sample size, highlighting the importance of interpreting results within the context of study limitations. ## Observations and Measurements: Interpreting Results Across Tools When LEfSe and ANCOM produce different results on the same dataset, the discrepancy itself is informative. Understanding why the tools disagree can reveal properties of the data that affect biomarker discovery. One common source of disagreement is the handling of rare taxa. LEfSe tends to identify rare taxa as differentially abundant if their relative abundance differs between groups, even when the absolute change is small. ANCOM's pairwise testing approach requires that a taxon differ from a substantial proportion of other taxa, which is harder for rare taxa to achieve. This difference explains why LEfSe often reports more differentially abundant taxa than ANCOM. Another source of disagreement is the direction of association. A study of chemotherapy toxicity found that while there was moderate concordance in effect-size rankings across methods, the direction of association for some taxa differed between tools [3]. This means that a taxon might be reported as enriched in one group by LEfSe but depleted in the same group by ANCOM-BC. Such discrepancies are concerning because they would lead to opposite biological interpretations. The choice of multiple testing correction also affects results. LEfSe does not apply a multiple testing correction by default, although researchers can apply Benjamini-Hochberg correction to the Kruskal-Wallis p-values before the LDA step. ANCOM's pairwise testing inherently involves multiple comparisons, and the tool applies its own correction based on the proportion of significant pairwise tests. ANCOM-BC provides adjusted p-values using standard FDR methods. A study of gut microbiota in childhood obesity treatment used both ANCOM-BC and LEfSe in a complementary manner [4]. The researchers used ANCOM-BC for differential abundance analysis and LEfSe for exploratory biomarker discovery, then used a random forest classifier to identify the most influential features. This multi-method approach allowed them to identify Faecalibacterium as the most important predictor of treatment response, a finding that was supported by both differential abundance and predictive modeling. ## Records and Documentation for Reproducibility Reproducibility is a core requirement for microbiome research, and the choice of differential abundance tool is a critical component of the analysis record. Researchers should document the exact version of each tool, the parameters used, the normalization method, the zero-handling strategy, and the multiple testing correction applied. This information should be included in the methods section of any publication and in the analysis code or workflow. The [nf-core documentation](https://nf-co.re/docs) describes community standards for reproducible bioinformatics pipelines, including version control, containerization, and parameter documentation. The [Bioconductor](https://bioconductor.org/) project provides official package documentation and versioned releases, which helps ensure that analyses can be reproduced with the same tool versions. The [Galaxy Training Network](https://training.galaxyproject.org/) offers tutorials that emphasize reproducible workflow design. Version control is essential for tracking changes to analysis code and parameters. The [Carpentries lessons](https://carpentries.org/lessons) provide foundational training in Git and shell scripting that is directly applicable to managing bioinformatics workflows. Researchers should commit their analysis scripts, parameter files, and environment specifications to a version control repository to ensure that the analysis can be reproduced or modified in the future. The feature table and mapping file should also be archived in a public repository. The [NCBI Data Resources](https://www.ncbi.nlm.nih.gov/) provide access to sequence read archives and other databases where raw sequencing data can be deposited. Public data deposition enables other researchers to reanalyze the data with different tools or parameters, which is essential for validating biomarker discoveries. ## Common Failure Patterns in Differential Abundance Analysis Several recurring problems undermine differential abundance analysis in microbiome studies. Recognizing these failure patterns can help researchers avoid them or interpret their results appropriately. The first failure pattern is ignoring compositionality. Tools that do not account for the compositional structure of microbiome data, including LEfSe, can produce false positives driven by changes in other taxa. This problem is particularly severe when the overall community composition differs substantially between groups, as the closure effect amplifies spurious differences. Researchers who use LEfSe without compositional correction should validate their findings with a compositional tool. The second failure pattern is overinterpreting results from small samples. Microbiome data are high-dimensional, with thousands of taxa measured in relatively few samples. This creates a multiple testing problem that is difficult to manage even with FDR correction. A study of temporal lobe epilepsy with 30 patients per arm found that ANCOM-BC identified species-level signatures, but the researchers explicitly cautioned that these findings were exploratory and hypothesis-generating given the modest sample size [2]. Small studies should be interpreted as generating hypotheses, not confirming them. The third failure pattern is relying on a single tool. The limited overlap in detected taxa across differential abundance methods means that results from any single tool are unlikely to capture the full picture. A study of chemotherapy toxicity found substantial variability across six methods with limited overlap in detected taxa but moderate concordance in effect-size rankings [3]. Researchers should use multiple tools and focus on taxa that are consistently identified across methods. The fourth failure pattern is neglecting validation. Biomarker discoveries from differential abundance analysis should be validated in independent datasets or through complementary methods such as quantitative PCR or metagenomic sequencing. A study of gut microbiota in endometriosis and inflammatory bowel disease identified specific taxa associated with disease status, but the authors emphasized the need for validation in larger cohorts combined with metagenomic and metabolomic approaches [5]. The fifth failure pattern is confusing correlation with causation. Differential abundance analysis identifies taxa that differ between groups, but it does not establish that those taxa cause the observed phenotype. The gut microbiota is a complex ecosystem, and changes in one taxon may be a consequence of changes in others or of the underlying disease process. Researchers should be cautious in their interpretations and avoid overstating the biological significance of differential abundance results. ## Limitations of LEfSe and ANCOM Both LEfSe and ANCOM have inherent limitations that researchers should understand before choosing a tool. LEfSe's primary limitation is its lack of compositional awareness. The method treats relative abundances as if they were independent measurements, which violates the mathematical properties of compositional data. This can lead to false positives, particularly when the overall community composition differs between groups. LEfSe also assumes that features are normally distributed within groups for the LDA step, an assumption that rarely holds for microbiome count data. The LDA scores are not directly interpretable as effect sizes in the traditional sense, and they cannot be compared across studies. ANCOM's primary limitation is its conservative nature. The pairwise testing approach requires that a taxon differ from a substantial proportion of other taxa to be declared significant, which reduces sensitivity for taxa that change in concert with many others. The original ANCOM does not provide effect size estimates, limiting its utility for meta-analysis. ANCOM-BC addresses this limitation but introduces its own assumptions about sampling fractions that may not hold in all datasets. Both tools struggle with sparse data. The high proportion of zeros in microbiome feature tables creates challenges for any statistical method. LEfSe treats zeros as absent, which can bias results if zeros are not randomly distributed. ANCOM's log-ratio transformation cannot handle zeros without a pseudocount or zero-replacement strategy, and the choice of strategy can affect results. Researchers should explore the sensitivity of their findings to the zero-handling method. The computational requirements of ANCOM can be prohibitive for large datasets. The pairwise testing approach scales quadratically with the number of taxa, which can be slow for datasets with thousands of taxa. ANCOM-BC is more efficient but still more computationally intensive than LEfSe. Researchers working with large datasets should consider whether the computational cost is justified by the improved FDR control. ## Safety and Regulatory Context for Biomarker Claims Microbiome biomarkers identified through differential abundance analysis have potential clinical applications, but these applications are subject to regulatory oversight. Researchers who intend to develop diagnostic or prognostic tests based on microbiome biomarkers should be aware of the regulatory requirements that apply to such tests. The [NCBI Data Resources](https://www.ncbi.nlm.nih.gov/) provide access to databases that can support biomarker validation, including clinical trial registries and genetic databases. The [EMBL-EBI Training](https://www.ebi.ac.uk/training) portal offers resources on data standards and reporting guidelines that are relevant to regulatory submissions. Researchers should consult these resources early in the biomarker development process. The exploratory nature of most differential abundance studies means that findings should not be used for clinical decisions without extensive validation. A study of gut microbiota in childhood obesity treatment found that baseline microbiota composition predicted treatment response, but the authors emphasized that their findings required validation in larger cohorts [4]. Similarly, a study of endometriosis and inflammatory bowel disease identified microbial signatures associated with disease status, but the authors noted that the findings highlighted potential for microbiome-based diagnostics instead of established tests [5]. Researchers should also be aware of the ethical considerations surrounding microbiome research. Stool samples contain genetic information from both the host and the microbial community, and participants should provide informed consent for the use of their samples in research. Data sharing should be conducted in accordance with applicable privacy regulations, and researchers should be transparent about the limitations of their findings. ## Professional Escalation Criteria Researchers should escalate concerns to a bioinformatics specialist or statistician when they encounter specific problems in differential abundance analysis. The following situations warrant professional consultation. If LEfSe and ANCOM produce substantially different results with limited overlap in detected taxa, a statistician should review the analysis to identify the source of the discrepancy. The discrepancy may indicate a problem with normalization, zero handling, or the statistical model that requires expert attention. If the false discovery rate is unacceptably high, as indicated by a large number of significant taxa with small effect sizes, a statistician should review the multiple testing correction strategy. The choice of FDR method and the threshold for significance can substantially affect results, and expert guidance may be needed to select appropriate parameters. If the results are sensitive to small changes in preprocessing parameters, such as the pseudocount added for log-ratio transformation or the normalization method, the analysis may not be robust. A bioinformatics specialist can help identify the source of instability and recommend more robust approaches. If the study involves a regulatory submission or clinical decision, a statistician with expertise in diagnostic test development should be consulted. The statistical requirements for regulatory approval are more stringent than those for exploratory research, and expert guidance is essential. If the dataset has unusual features, such as extreme sparsity, batch effects, or a complex experimental design, a bioinformatics specialist should review the analysis plan before differential abundance testing begins. These features can invalidate the assumptions of standard tools and require specialized approaches. ## A Practical Decision Framework for LEfSe and ANCOM Selection Choosing between LEfSe and ANCOM requires more than understanding their statistical foundations. Researchers need a structured approach that maps study characteristics to tool selection, accounts for the analytical context, and defines clear criteria for when to escalate to more rigorous methods. The following framework translates the methodological differences between these tools into concrete decisions that can be applied before any analysis begins. ### Step 1: Classify Your Study Objective The first decision point is the primary purpose of the differential abundance analysis. Studies fall into three broad categories, each with different tolerance for false positives and different requirements for statistical rigor. **Exploratory screening studies** aim to generate candidate biomarkers for later validation. These studies typically have small sample sizes, broad research questions, and no prior hypotheses about specific taxa. The goal is to cast a wide net and identify as many potential signals as possible. LEfSe is appropriate for this context because its high sensitivity ensures that candidate taxa are not missed, even at the cost of a higher false positive rate. A benchmark study comparing eight differential abundance tools found that LEfSe achieved high sensitivity but failed to adequately control the false discovery rate, making it suitable for screening but not for confirmation [1]. **Confirmatory validation studies** test specific hypotheses about taxa that were identified in previous work or are supported by biological plausibility. These studies require strict false discovery rate control because the results will inform subsequent experiments or clinical decisions. ANCOM or ANCOM-BC is the appropriate choice because these tools explicitly model compositionality and control FDR in benchmark evaluations [1]. The reduced sensitivity of ANCOM is an acceptable trade-off when the research question is narrowly defined and the candidate taxa are already specified. **Multi-method discovery studies** integrate both approaches in a single analysis pipeline. This design uses LEfSe for initial screening, then validates the candidate taxa with ANCOM or ANCOM-BC. A study of gut microbiota in temporal lobe epilepsy used LEfSe with Benjamini-Hochberg false-discovery-rate correction for initial assessment, then independently validated the findings using ANCOM-BC to account for the compositional nature of microbiome data [2]. This approach provides the sensitivity of LEfSe and the specificity of ANCOM, with the overlap between methods indicating the most reliable biomarker candidates. ### Step 2: Assess Your Data Characteristics The structure of the dataset determines whether the assumptions of each tool are likely to hold. Three data characteristics are particularly important. **Compositional heterogeneity** refers to the degree to which the overall community composition differs between comparison groups. When groups have substantially different microbial loads or community structures, the closure effect is amplified and tools that ignore compositionality produce more false positives. ANCOM and ANCOM-BC are designed to handle this situation through log-ratio transformations. LEfSe does not explicitly account for compositionality, so its results become less reliable as compositional heterogeneity increases. **Sparsity level** describes the proportion of zeros in the feature table. Highly sparse data, where many taxa are present in only a small fraction of samples, create challenges for both tools. LEfSe treats zeros as absent, which can bias results if zeros are not randomly distributed across groups. ANCOM's log-ratio transformation cannot handle zeros directly and requires a pseudocount or zero-replacement strategy. The choice of zero-handling method can affect results, and researchers should document this decision and explore its impact on findings. **Sample size and group balance** affect the statistical power of both tools. A study of chemotherapy toxicity in colorectal cancer patients evaluated six differential abundance methods and found substantial variability across methods with limited overlap in detected taxa [3]. The researchers noted that trade-offs remained between taxa detection, ranking, and direction of association, even for the most consistent tool. Small sample sizes amplify these trade-offs, and findings from studies with fewer than 30 samples per group should be regarded as exploratory and hypothesis-generating instead of definitive [2]. ### Step 3: Evaluate the Consequences of Errors The relative cost of false positives versus false negatives should guide tool selection. This cost depends on how the results will be used. **High cost of false positives** occurs when differentially abundant taxa will be pursued in downstream experiments, used to guide clinical decisions, or reported as definitive biomarkers. In these contexts, ANCOM or ANCOM-BC is preferred because these tools control the false discovery rate. A study of gut microbiota in childhood obesity treatment used ANCOM-BC for differential abundance analysis and LEfSe for exploratory biomarker discovery, then used a random forest classifier to identify the most influential features [4]. The researchers emphasized that their findings required validation in larger cohorts, reflecting the high cost of false positives in clinical research. **High cost of false negatives** occurs when missing a true biomarker would be detrimental, such as in early-stage discovery where the goal is to identify all potential signals for further investigation. LEfSe is appropriate in this context because its high sensitivity ensures that true differences are not missed. The trade-off is that many of the identified taxa will be false positives, so the results must be interpreted as candidates for validation instead of confirmed biomarkers. **Balanced costs** occur in most academic research settings where the results will inform future studies but will not directly guide clinical decisions. In these contexts, a multi-method approach that uses both LEfSe and ANCOM provides the most informative results. Taxa that are significant in both analyses are strong candidates, while taxa significant in only one tool should be interpreted with caution. ### Step 4: Document the Decision and Analysis Parameters The decision framework should be documented before the analysis begins to prevent bias and ensure reproducibility. The documentation should include the study objective classification, the data characteristics that were assessed, the rationale for tool selection, and the specific parameters used for each tool. The [nf-core documentation](https://nf-co.re/docs) describes community standards for reproducible bioinformatics pipelines, including version control, containerization, and parameter documentation. The [Bioconductor](https://bioconductor.org/) project provides official package documentation and versioned releases, which helps ensure that analyses can be reproduced with the same tool versions. The [Galaxy Training Network](https://training.galaxyproject.org/) offers tutorials that emphasize reproducible workflow design. The documentation should also include the normalization method, the zero-handling strategy, and the multiple testing correction applied. A study introducing the metaGEENOME framework found that integrating counts adjusted with trimmed mean of M-values normalization and centered log-ratio transformation with generalized estimating equation models improved FDR control compared to several existing tools [1]. This finding underscores that normalization is an active component of the statistical model, not a neutral preprocessing step. ### Step 5: Apply Escalation Criteria The decision framework includes specific criteria for escalating to professional consultation. Researchers should seek guidance from a bioinformatics specialist or statistician when any of the following conditions are met. **Discrepancy between tools** occurs when LEfSe and ANCOM produce substantially different results with limited overlap in detected taxa. A study of chemotherapy toxicity found substantial variability across six methods with limited overlap in detected taxa but moderate concordance in effect-size rankings [3]. When this pattern emerges, a statistician should review the analysis to identify the source of the discrepancy, which may indicate a problem with normalization, zero handling, or the statistical model. **Unstable results** occur when findings are sensitive to small changes in preprocessing parameters, such as the pseudocount added for log-ratio transformation or the normalization method. This instability suggests that the analysis is not robust and that the results should not be interpreted with confidence. A bioinformatics specialist can help identify the source of instability and recommend more robust approaches. **Regulatory or clinical implications** require consultation with a statistician with expertise in diagnostic test development. The statistical requirements for regulatory approval are more stringent than those for exploratory research, and the choice of differential abundance tool is a critical component of the validation strategy. The [NCBI Data Resources](https://www.ncbi.nlm.nih.gov/) provide access to databases that can support biomarker validation, including clinical trial registries and genetic databases. **Complex data structures** such as extreme sparsity, batch effects, or longitudinal designs require specialized approaches. A study of gut microbiota in endometriosis and inflammatory bowel disease used longitudinal sampling to assess microbial stability and found that persistent dysbiotic signatures correlated with disease severity [5]. Standard differential abundance tools may not adequately handle these complex designs, and professional consultation is warranted before analysis begins. ### Implementing the Framework in Practice The decision framework can be implemented as a structured checklist that is completed before any differential abundance analysis is performed. The checklist should include the study objective classification, the data characteristics assessment, the error cost evaluation, the tool selection rationale, and the documentation plan. This checklist serves as a record of the analytical decisions and provides a basis for interpreting the results. A study of gut microbiota in childhood obesity treatment illustrates the practical application of this framework. The researchers used ANCOM-BC for differential abundance analysis and LEfSe for exploratory biomarker discovery, then used a random forest classifier to identify the most influential features [4]. The multi-method approach allowed them to identify Faecalibacterium as the most important predictor of treatment response, a finding that was supported by both differential abundance and predictive modeling. The researchers also used receiver operating characteristic curve analysis to determine a Simpson index cut-off that stratified participants into high- and low-diversity groups, demonstrating the integration of multiple analytical approaches. The framework also guides the interpretation of results. When LEfSe and ANCOM agree on a set of differentially abundant taxa, those taxa are strong biomarker candidates. When the tools disagree, the discrepancy should be investigated instead of ignored. The direction of association can also differ between tools, as observed in the chemotherapy toxicity study where some taxa were reported as enriched in one group by one tool but depleted in the same group by another [3]. These discrepancies are informative and should be reported transparently. The decision framework is not a substitute for statistical expertise, but it provides a structured approach that helps researchers make informed choices before committing to an analysis pipeline. By classifying the study objective, assessing data characteristics, evaluating error costs, documenting decisions, and applying escalation criteria, researchers can select the appropriate tool for their specific context and interpret the results with appropriate confidence. ## Frequently Asked Questions ### What is the main difference between LEfSe and ANCOM? LEfSe uses a nonparametric Kruskal-Wallis test followed by linear discriminant analysis to identify features that distinguish between groups. ANCOM uses log-ratio transformations to account for the compositional nature of microbiome data and tests each taxon against all others in pairwise comparisons. The main difference is that ANCOM explicitly models compositionality while LEfSe does not, which affects false discovery rates and the reliability of results. ### Which tool should I use for exploratory analysis? LEfSe is well suited for exploratory analysis because it has high sensitivity and will identify many candidate biomarkers. The trade-off is a higher false positive rate, so LEfSe results should be treated as hypotheses to be validated with more rigorous methods. For exploratory screening where the goal is to generate candidates, LEfSe is a reasonable starting point. ### Which tool should I use for confirmatory analysis? ANCOM or ANCOM-BC is preferred for confirmatory analysis because these tools control the false discovery rate and account for the compositional structure of microbiome data. ANCOM-BC provides effect size estimates with confidence intervals, which are useful for comparing results across studies. The trade-off is reduced sensitivity, so some true differences may be missed. ### Can I use both LEfSe and ANCOM in the same study? Yes, using both tools in a complementary manner is a common and recommended approach. LEfSe can be used for initial exploratory screening to generate candidate biomarkers, and ANCOM or ANCOM-BC can be used to validate those candidates. Taxa that are significant in both analyses are strong biomarker candidates, while taxa significant in only one tool should be interpreted with caution. ### How does compositionality affect differential abundance results? Compositionality means that the relative abundance of each taxon is constrained by the abundances of all other taxa. If one taxon increases, the relative proportions of others must decrease even if their absolute abundances are unchanged. Tools that ignore compositionality can produce false positives by attributing these spurious changes to biological differences. ANCOM and ANCOM-BC use log-ratio transformations to address this problem. ### What is the difference between ANCOM and ANCOM-BC? ANCOM tests each taxon against all others in pairwise comparisons and declares a taxon significant if a substantial proportion of comparisons reject the null hypothesis. ANCOM-BC adds a bias correction step that estimates sampling fractions and provides effect size estimates with confidence intervals. ANCOM-BC is generally preferred because it provides more interpretable results and better statistical properties. ### How should I handle zeros in my feature table? Zeros are a common challenge in microbiome data because many taxa are present in only a subset of samples. LEfSe treats zeros as absent, which can bias results if zeros are not randomly distributed. ANCOM's log-ratio transformation cannot handle zeros directly, so a pseudocount or zero-replacement strategy is needed. The choice of strategy can affect results, and researchers should explore the sensitivity of their findings to this choice. ### What sample size do I need for reliable differential abundance analysis? There is no simple answer to this question because the required sample size depends on the effect size, the number of taxa, the variability between samples, and the statistical power desired. Studies with fewer than 30 samples per group are generally considered exploratory, and findings should be validated in larger cohorts. Researchers should consult a statistician to perform a power analysis before designing a study. ## Related Bioinformatics Guides - [RNA-Seq Alignment: Choosing the Right Tool and Parameters](/knowledge/bioinformatics/rna-seq-alignment-choosing-the-right-tool-and-parameters) - [Gene Set Enrichment Analysis Tools: Choosing the Right One](/knowledge/bioinformatics/gene-set-enrichment-analysis-tools-choosing-the-right-one) - [Multi-Omics Data Integration: A Comparative Framework for Choosing the Right Method](/knowledge/bioinformatics/multi-omics-data-integration-a-comparative-framework-for-choosing-the-right-method) - [Microbiome Data Analysis in R: A Practical Guide for Compositional Data](/knowledge/bioinformatics/microbiome-data-analysis-in-r-a-practical-guide-for-compositional-data) - [Metagenomics vs Metabarcoding: Choosing the Right Approach for Your Study](/knowledge/bioinformatics/metagenomics-vs-metabarcoding-choosing-the-right-approach-for-your-study) ## Related Clinical & Scientific Guides * [A Practical Guide to Detecting Antimicrobial Resistance Genes in Shotgun Metagenomic Data](/knowledge/bioinformatics/a-practical-guide-to-detecting-antimicrobial-resistance-genes-in-shotgun-metagenomic-data) * [Computational Immunology: Modeling the Immune System](/knowledge/bioinformatics/computational-immunology-modeling-the-immune-system) * [How to Set Hard Filters for Germline Variant Calling: A Practical Guide to GATK Best Practices](/knowledge/bioinformatics/how-to-set-hard-filters-for-germline-variant-calling-a-practical-guide-to-gatk-best-practices) ## References and Further Reading [1] [metaGEENOME: an integrated framework for differential abundance analysis of microbiome data in cross-sectional and longitudinal studies.](https://pubmed.ncbi.nlm.nih.gov/40691525). BMC bioinformatics, 2025. [2] [Gut microbiota profiles associated with temporal lobe epilepsy and psychiatric comorbidities: a family-matched case-control 16S rRNA study.](https://pubmed.ncbi.nlm.nih.gov/42121077). BMC neurology, 2026. [3] [Microbiome differential abundance methodologies to detect relevant taxa associated with chemotherapy toxicity rate in colorectal cancer.](https://pubmed.ncbi.nlm.nih.gov/42381925). Bioinformatics advances, 2026. [4] [Children's gut microbiota predicts the efficacy of obesity treatment.](https://pubmed.ncbi.nlm.nih.gov/41711285). Gut microbes, 2026. [5] [Gut microbial signatures and stability are associated with a co-diagnosis of endometriosis and inflammatory bowel disease.](https://doi.org/10.1016/j.isci.2026.115437). 2026. > This article is educational and does not replace validated analysis plans, institutional policy, clinical interpretation, or specialist review.